CA2799162A1 - Traitement du tcl et de la maladie d'alzheimer - Google Patents

Traitement du tcl et de la maladie d'alzheimer Download PDF

Info

Publication number
CA2799162A1
CA2799162A1 CA2799162A CA2799162A CA2799162A1 CA 2799162 A1 CA2799162 A1 CA 2799162A1 CA 2799162 A CA2799162 A CA 2799162A CA 2799162 A CA2799162 A CA 2799162A CA 2799162 A1 CA2799162 A1 CA 2799162A1
Authority
CA
Canada
Prior art keywords
nifedipine
pharmaceutical composition
nitroso
lactam
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2799162A
Other languages
English (en)
Inventor
Mark Lovell
Bert Lynn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kentucky Research Foundation
Original Assignee
University of Kentucky Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2010/034721 external-priority patent/WO2010132671A1/fr
Application filed by University of Kentucky Research Foundation filed Critical University of Kentucky Research Foundation
Publication of CA2799162A1 publication Critical patent/CA2799162A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2799162A 2010-05-13 2010-11-18 Traitement du tcl et de la maladie d'alzheimer Abandoned CA2799162A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2010/034721 WO2010132671A1 (fr) 2009-05-15 2010-05-13 Traitement du trouble cognitif léger et de la maladie d'alzheimer
USPCT/US2010/034721 2010-05-13
PCT/US2010/057287 WO2011142778A1 (fr) 2010-05-13 2010-11-18 Traitement du tcl et de la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
CA2799162A1 true CA2799162A1 (fr) 2011-11-17

Family

ID=44923820

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2799162A Abandoned CA2799162A1 (fr) 2010-05-13 2010-11-18 Traitement du tcl et de la maladie d'alzheimer

Country Status (6)

Country Link
EP (1) EP2568811A4 (fr)
JP (1) JP2013526518A (fr)
CN (1) CN102984938A (fr)
AU (1) AU2010353287A1 (fr)
CA (1) CA2799162A1 (fr)
WO (1) WO2011142778A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2994160T (lt) * 2013-05-06 2019-08-26 Baxalta Incorporated Alzheimerio ligos pogrupių gydymas su iš kelių donorų sumaišytu imunoglobulinu g
CN111426848A (zh) 2013-06-28 2020-07-17 株式会社 Mcbi 认知功能障碍疾病的生物标记物及使用该生物标记物的认知功能障碍疾病的检测方法
JP6276865B2 (ja) * 2014-01-29 2018-02-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アリールラクタムキナーゼ阻害剤
CN106177046A (zh) * 2016-08-29 2016-12-07 杨添福 一种基于普立宁钾开发的神经认知障碍治疗药物及其制备方法
CN106645505A (zh) * 2016-11-18 2017-05-10 中国医科大学 可实现glt‑1蛋白鉴定及绝对定量的试剂盒及测定方法
CN107022019B (zh) * 2016-11-24 2020-10-30 桂林医学院 一种用于脑内降铁除自由基的多肽、制备方法与应用
CN106636388A (zh) * 2016-12-15 2017-05-10 湖南中能荆卫生物科技有限公司 用于亨廷顿病诊断的基因及其应用以及由其编码的蛋白和蛋白的应用
CN108191966B (zh) * 2018-01-11 2020-10-27 桂林医学院 一种含导肽可穿越血脑屏障螯合脑内铁降自由基的多肽
KR20220004618A (ko) * 2019-01-07 2022-01-11 세나 바이오사이언스 아이엔씨. 신규한 펩티드 및 이의 용도
JP7321017B2 (ja) * 2019-07-17 2023-08-04 東海物産株式会社 機能性食品

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8002A (en) * 1851-03-25 Upright pianoforte
DE2126533A1 (de) * 1971-05-28 1972-12-14 Merck Patent Gmbh, 6100 Darmstadt Verfahren zur Herstellung pharma zeutischer Zubereitungen
US6558650B1 (en) * 1998-04-08 2003-05-06 Oregon Health And Science University Enhancement of cellular gallium uptake
US6489319B2 (en) * 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
CN1479616A (zh) * 2000-11-21 2004-03-03 霍华德・齐克 使用1,4-二氢吡啶钙通道阻断剂治疗疱疹神经病毒病症
WO2005051389A1 (fr) * 2003-11-21 2005-06-09 Memory Pharmaceuticals Corporation Utilisation de (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dymethyl-pyridine-3,5-dicarboxylate pour traiter des troubles de la memoire
EP1874311B1 (fr) * 2005-04-15 2011-10-05 Research & Innovation S.p.A. Methode pour prevenir, retarder ou inverser la progression de pathologies associees a un depot amyloide anormal
US20090286879A1 (en) * 2005-12-02 2009-11-19 Kiyoshi Hashizume Preventive or Therapeutic Drug for Alzheimer-Type Dementia
US20100029654A1 (en) * 2006-03-23 2010-02-04 Mount Sinai School Of Medicine Cardiovascular compositions and use of the same for the treatment of alzheimer's disease
CA2648243C (fr) * 2006-04-11 2015-12-22 Shaker A. Mousa Nanoparticule et formes polymeres d'analogues et d'antagonistes de l'hormone thyroidienne et leurs formulations
WO2008109613A1 (fr) * 2007-03-05 2008-09-12 Wyeth Dérivés de benzo[c][2,7]naphtyridine et leur utilisation en tant qu'inhibiteurs de kinase
CA2737618A1 (fr) * 2008-09-25 2010-04-01 Merck Frosst Canada Ltd. Derives de beta-carboline sulfonyluree en tant qu'antagonistes du recepteur d'ep4
TW201103907A (en) * 2009-03-20 2011-02-01 Lundbeck & Co As H Amide derivatives as neuropeptide Y5 receptor ligands

Also Published As

Publication number Publication date
EP2568811A1 (fr) 2013-03-20
EP2568811A4 (fr) 2014-03-12
CN102984938A (zh) 2013-03-20
AU2010353287A1 (en) 2012-11-29
WO2011142778A1 (fr) 2011-11-17
JP2013526518A (ja) 2013-06-24

Similar Documents

Publication Publication Date Title
CA2799162A1 (fr) Traitement du tcl et de la maladie d'alzheimer
US20100292281A1 (en) Treatment of mci and alzheimer's disease
JP2012526844A5 (fr)
US9968574B2 (en) Treatment of MCI and Alzheimer's disease
Pohanka Alzheimer s disease and oxidative stress: a review
Fernandez‐Perez et al. Synaptic dysregulation and hyperexcitability induced by intracellular amyloid beta oligomers
KR20110071050A (ko) 알츠하이머 질환 및 관련 장애의 치료를 위한 조니사미드 및 아캄프로세이트의 조합 조성물
WO2008006070A2 (fr) Composés et combinaisons de ceux-ci pour inhiber la production de bêta-amyloïde et procédés d'utilisation de ces composés et combinaisons
KR20120055692A (ko) 화학요법에 의해 유도되는 통증의 예방 또는 치료를 위한 시그마 리간드
JP2016521755A (ja) 代謝障害を治療するための組成物および方法
WO2011050095A2 (fr) Prévention et traitement des dysfonctions cognitives postopératoires (pocd)
AU2017383127B2 (en) Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions
Sose et al. An Update on Autophagy as a Target in the Treatment of Alzheimer’s Disease
US20100247688A1 (en) Pirenzepine and derivatives thereof as anti-amyloid agents
KR101173677B1 (ko) Ｅｐｐｓ를 유효성분으로 함유하는 베타아밀로이드 집적 관련 질환의 예방 또는 치료용 약학적 조성물
Lovell et al. Treatment of MCI and Alzheimer's Disease
DK2462131T3 (en) Preparations and Methods for Treating Beta-Amyloid-Related Diseases
WO2024064897A1 (fr) Procédés de réduction de la neurodégénérescence associée à des maladies neurodégénératives
ES2449594T3 (es) Método para reducir deposición amiloide, neurotoxicidad amiloide y microgliosis con enantiomero (-)-nilvadipina
ES2374716T3 (es) Método para prevenir, retrasar o revertir la deposición anormal de amiloide.
Ranade et al. TARGET EVOLUTION AND THERAPY ADVANCEMENTS FOR ALZHEIMER’S DISEASE: A REVIEW
TW202438074A (zh) 噁二唑衍生物化合物及包含其之醫藥組合物
EP4725482A1 (fr) Activateur de glucokinase pour troubles cognitifs et maladies neurodégénératives
EA041317B1 (ru) Синергетические композиции, содержащие (r)-димирацетам (1) и (s)-димирацетам (2) в нерацемическом соотношении
KR20130030011A (ko) 뇌손상에 의한 전두엽 기능장애 모델 동물 및 전두엽 기능장애의 개선용 조성물

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20161118